AbbVie, Genentech and Pfizer Part of NIH Partnership to Accelerate the Development of New Cancer Immunotherapy Strategies for More Patients


The National Institutes of Health and 11 of the leading biopharma companies, including iBIO Members AbbVie, Genetech and Pfizer, launched the Partnership for Accelerating Canter Therapies (PACT). PACT will be a $215 Million five-year public-private research collaboration as part of the Cancer Moonshot. 

The collaboration will focus on efforts to identify, develop and validate robust biomarkers — standardized biological markers of disease and treatment response — to advance new immunotherapy treatments that harness the immune system to attack cancer. 

“Given the significant unmet needs that exist in oncology, it’s critical we work together to drive clinical research and development of innovative therapies that can ultimately make an impact on the lives of people around the world affected by cancer,” said Tom Hudson M.D., Vice President of Oncology Discovery and Early Development, AbbVie. “AbbVie applauds the efforts being made to drive forward innovation in oncology and we recognize that tackling the toughest challenges today is going to take all of us – scientists, physicians, industry peers, patient groups and most importantly patients.”

“We support PACT because collaboration is an important step that can lead to new breakthroughs and possibly even a chance for cure,” said Edith Perez, M.D., Vice President and Head of BioOncology Medical Affairs, Genentech, and Director of the Mayo Clinic Breast Cancer Translational Genomics Program. “When industry, academia and government work together to share scientific knowledge and new technologies, we have a chance to make significant strides in the fight against cancer and to ultimately help more people.” 

“Ensuring that cancer patients derive the maximum possible benefit from advances in immunotherapies is at the core of Pfizer’s Research & Development efforts. We are proud to support the PACT, and its urgent mission to work with the health innovation ecosystem to advance the impact of the latest cancer advances to a larger group of patients, in a timely fashion,” said Robert T. Abraham, Ph.D., Senior Vice President & Group Head, Oncology Research & Development, Pfizer Worldwide Research & Development.

PACT will facilitate systematic and uniform clinical testing of biomarkers to advance our understanding of the mechanisms of response and resistance to cancer therapy.  The research conducted under the partnership will also integrate immune and other related oncology biomarkers into clinical trials by defining a set of standardized biomarkers to be tested across a variety of studies. 

Click here to read more about PACT.

Share This Post:

Comments are closed.